HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment.

Journal Article

OBJECTIVES: We assessed the feasibility and preliminary efficacy of human immunodeficiency virus (HIV) testing with sexual risk reduction counseling for opioid-dependent patients initiating office-based buprenorphine/naloxone treatment. METHODS: We conducted a 14-week randomized, controlled trial with 30 patients (original target of 114) assigned to receive buprenorphine/naloxone induction/stabilization and HIV testing with Brief Sexual Risk Management (BSRM) or Enhanced Sexual Risk Management (ESRM). We evaluated process measures and compared outcomes at baseline and during the 3-month follow-up. RESULTS: Similar proportions of patients receiving BSRM and ESRM underwent HIV testing (93% vs 80%; P = 0.28) and completed counseling sessions (80% vs 67%; P = 0.40). Brief Sexual Risk Management sessions were shorter than ESRM sessions (15.4 vs 23.4 minutes), with comparable manual adherence (P = 0.80). Outcomes did not vary by BSRM versus ESRM. CONCLUSIONS: Although the recruitment of opioid-dependent patients with sexual risk behaviors is challenging, HIV testing with sexual risk reduction counseling in office-based buprenorphine/naloxone treatment practice is feasible. Interventions to decrease sexual risk behaviors among a segment of this population are necessary.

Full Text

Duke Authors

Cited Authors

  • Edelman, EJ; Moore, BA; Caffrey, S; Sikkema, KJ; Jones, ES; Schottenfeld, RS; Fiellin, DA; Fiellin, LE

Published Date

  • November 2013

Published In

Volume / Issue

  • 7 / 6

Start / End Page

  • 410 - 416

PubMed ID

  • 24189173

International Standard Serial Number (ISSN)

  • 1932-0620

Digital Object Identifier (DOI)

  • 10.1097/ADM.0b013e3182a3b603

Language

  • eng

Conference Location

  • United States